{"name":"Jordan Collaborating Cardiology Group","slug":"jordan-collaborating-cardiology-group","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Lansoprazole Pill","genericName":"Lansoprazole Pill","slug":"lansoprazole-pill","indication":"Gastroesophageal reflux disease (GERD)","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Pacebo","genericName":"Pacebo","slug":"pacebo","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"Lansoprazole Pill","genericName":"Lansoprazole Pill","slug":"lansoprazole-pill","phase":"marketed","mechanism":"Lansoprazole inhibits the proton pump in gastric parietal cells, reducing gastric acid secretion.","indications":["Gastroesophageal reflux disease (GERD)","Peptic ulcer disease","Zollinger-Ellison syndrome","Prevention of NSAID-induced ulcers"],"catalyst":""},{"name":"Pacebo","genericName":"Pacebo","slug":"pacebo","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxQdDc2RVl5MjJrZDFod1BXSHhXQnFydDBCQy0xWkRVdl9WZE1pMEI1YlpBRVA1YmVXeG5od2JjeDhrUkpuaTk4VDM4YUluY2M0NXE5UktBVnN1aGlyb25NeFotaEkyMldxUEg5NXlQOWNCSkgzMUFvX2pCTWotZ0I2b1ZR?oc=5","date":"2025-09-04","type":"pipeline","source":"وكالة الانباء الاردنية","summary":"Jordan convenes 6th Heart Valve Conference, spotlighting advances in transcatheter therapies - وكالة الانباء الاردنية","headline":"Jordan convenes 6th Heart Valve Conference, spotlighting advances in transcatheter therapies - وكالة الانباء الاردنية","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggJBVV95cUxOamhKLVJ4MnI4RHlWY19LMGVNOC1YZDhBLVU3d1V5OWt0UXhHNUpPZVJOcGxlMlNoZXpreWc0QTRTYTdMaTJVeGtYYzhxTTh6RGhMN1RONm9XVzNZeE1hblg3dnNQMTQ2aDdsZHI4YnFkaWVodlBhM0tZeXdodDNGODh5dFk2U3hzdU11VU9rTk10TzB1QkdpTUtQeEF4dzdVR1Q4UnBtZHFwLU1yaDJZYWlnMXc4VkZ5V1ByOURta243aVFlVkduY0t4eUpSSDNuYXRWVFhpQk9MSDdaQzVhRlJGcUNVWm0xR2VzOXBvSW1PMGhIb0NhV2ZJdkFHcnU3dlE?oc=5","date":"2024-09-11","type":"pipeline","source":"Business Wire","summary":"HAYA Therapeutics Appoints Cardiology and Genetics Medicines Expert Jordan Shin, M.D., Ph.D. as Chief Medical Officer - Business Wire","headline":"HAYA Therapeutics Appoints Cardiology and Genetics Medicines Expert Jordan Shin, M.D., Ph.D. as Chief Medical Officer","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"marketed":1,"phase_1":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}